BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Acanfora D, Ciccone MM, Scicchitano P, Acanfora C, Casucci G. Neprilysin inhibitor-angiotensin II receptor blocker combination (sacubitril/valsartan): rationale for adoption in SARS-CoV-2 patients. Eur Heart J Cardiovasc Pharmacother 2020;6:135-6. [PMID: 32282032 DOI: 10.1093/ehjcvp/pvaa028] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 14.0] [Reference Citation Analysis]
Number Citing Articles
1 Sriram K, Loomba R, Insel PA. Targeting the renin-angiotensin signaling pathway in COVID-19: Unanswered questions, opportunities, and challenges. Proc Natl Acad Sci U S A 2020;117:29274-82. [PMID: 33203679 DOI: 10.1073/pnas.2009875117] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
2 Bellis A, Mauro C, Barbato E, Trimarco B, Morisco C. The Rationale for Angiotensin Receptor Neprilysin Inhibitors in a Multi-Targeted Therapeutic Approach to COVID-19. Int J Mol Sci 2020;21:E8612. [PMID: 33203141 DOI: 10.3390/ijms21228612] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
3 Mahajan K, Chand Negi P, Ganju N, Sondhi S, Gaur N, Somendra R. Renin-Angiotensin System Inhibitors in COVID-19: Current Concepts. Int J Hypertens 2020;2020:1025913. [PMID: 33145103 DOI: 10.1155/2020/1025913] [Reference Citation Analysis]
4 Inchingolo AD, Inchingolo AM, Bordea IR, Malcangi G, Xhajanka E, Scarano A, Lorusso F, Farronato M, Tartaglia GM, Isacco CG, Marinelli G, D'Oria MT, Hazballa D, Santacroce L, Ballini A, Contaldo M, Inchingolo F, Dipalma G. SARS-CoV-2 Disease Adjuvant Therapies and Supplements Breakthrough for the Infection Prevention. Microorganisms 2021;9:525. [PMID: 33806624 DOI: 10.3390/microorganisms9030525] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 8.0] [Reference Citation Analysis]
5 Rex DAB, Arun Kumar ST, Modi PK, Keshava Prasad TS. Broadening COVID-19 Interventions to Drug Innovation: Neprilysin Pathway as a Friend, Foe, or Promising Molecular Target? OMICS 2021;25:408-16. [PMID: 34191617 DOI: 10.1089/omi.2021.0080] [Reference Citation Analysis]
6 Gurwitz D. Repurposing current therapeutics for treating COVID-19: A vital role of prescription records data mining. Drug Dev Res 2020;81:777-81. [PMID: 32420637 DOI: 10.1002/ddr.21689] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
7 Casucci G, Acanfora D, Incalzi RA. The Cross-Talk between Age, Hypertension and Inflammation in COVID-19 Patients: Therapeutic Targets. Drugs Aging 2020;37:779-85. [PMID: 33084001 DOI: 10.1007/s40266-020-00808-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
8 Agewall S. Can we offer tailor-made pharmacological treatment of patients with acute coronary syndrome? European Heart Journal - Cardiovascular Pharmacotherapy 2020;6:201-2. [DOI: 10.1093/ehjcvp/pvaa075] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
9 Pallarés Carratalá V, Górriz-Zambrano C, Morillas Ariño C, Llisterri Caro JL, Gorriz JL. [COVID-19 and cardiovascular and kidney disease: Where are we? Where are we going?]. Semergen 2020;46 Suppl 1:78-87. [PMID: 32448633 DOI: 10.1016/j.semerg.2020.05.005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
10 Roganović JR. microRNA‐146a and ‐155, upregulated by periodontitis and type 2 diabetes in oral fluids, are predicted to regulate SARS‐CoV‐2 oral receptor genes. J Periodontol 2021;92. [DOI: 10.1002/jper.20-0623] [Reference Citation Analysis]
11 Teng S, Tang Q. ACE2 enhance viral infection or viral infection aggravate the underlying diseases. Comput Struct Biotechnol J 2020;18:2100-6. [PMID: 32832038 DOI: 10.1016/j.csbj.2020.08.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
12 Acanfora D, Ciccone MM, Scicchitano P, Acanfora C, Casucci G. Sacubitril/valsartan in COVID-19 patients: the need for trials. Eur Heart J Cardiovasc Pharmacother 2020;6:253-4. [PMID: 32369103 DOI: 10.1093/ehjcvp/pvaa044] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
13 Ruilope LM, Tamargo J, Ruiz-Hurtado G. Renin-angiotensin system inhibitors in the COVID-19 pandemic: consequences of antihypertensive drugs. Eur Heart J 2020;41:2067-9. [PMID: 32498078 DOI: 10.1093/eurheartj/ehaa487] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
14 Manolis AS, Manolis TA, Manolis AA, Melita H. The Controversy of Renin-Angiotensin-System Blocker Facilitation Versus Countering COVID-19 Infection. J Cardiovasc Pharmacol 2020;76:397-406. [PMID: 32769760 DOI: 10.1097/FJC.0000000000000894] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 4.5] [Reference Citation Analysis]
15 Rubattu S, Gallo G, Volpe M. A Contemporary View of Natriuretic Peptides in the SARS-CoV-2 Era. Front Physiol 2021;12:643721. [PMID: 34335287 DOI: 10.3389/fphys.2021.643721] [Reference Citation Analysis]
16 Rubattu S, Gallo G, Volpe M. Sacubitril/Valsartan: Potential Impact of ARNi "Beyond the Wall" of ACE2 on Treatment and Prognosis of Heart Failure Patients With Coronavirus Disease-19. Front Cardiovasc Med 2020;7:616564. [PMID: 33330677 DOI: 10.3389/fcvm.2020.616564] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
17 Petramala L, Letizia C. Response to: Neprilysin inhibitor-angiotensin II receptor blocker combination (sacubitril/valsartan). Eur Heart J Cardiovasc Pharmacother 2020;6:252. [PMID: 32352509 DOI: 10.1093/ehjcvp/pvaa035] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
18 Pucci F, Bogaerts P, Rooman M. Modeling the Molecular Impact of SARS-CoV-2 Infection on the Renin-Angiotensin System. Viruses 2020;12:E1367. [PMID: 33265982 DOI: 10.3390/v12121367] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
19 Wang H, Jing ZC. Inflammation and cardiovascular diseases. Chronic Dis Transl Med 2020;6:215-8. [PMID: 33336166 DOI: 10.1016/j.cdtm.2020.09.003] [Reference Citation Analysis]
20 Babajani F, Kakavand A, Mohammadi H, Sharifi A, Zakeri S, Asadi S, Afshar ZM, Rahimi Z, Sayad B. COVID-19 and renin angiotensin aldosterone system: Pathogenesis and therapy. Health Sci Rep 2021;4:e440. [PMID: 34869917 DOI: 10.1002/hsr2.440] [Reference Citation Analysis]
21 Esser N, Zraika S. Neprilysin Inhibitors and Angiotensin(1-7) in COVID-19. Br J Cardiol 2020;27:109-11. [PMID: 33795925 DOI: 10.5837/bjc.2020.031] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
22 Acanfora D, Nolano M, Acanfora C, Colella C, Provitera V, Caporaso G, Rodolico GR, Bortone AS, Galasso G, Casucci G. Impaired Vagal Activity in Long-COVID-19 Patients. Viruses 2022;14:1035. [DOI: 10.3390/v14051035] [Reference Citation Analysis]
23 Agewall S. Adherence to pharmacological treatment: how can we improve? Eur Heart J Cardiovasc Pharmacother 2021;7:261-2. [PMID: 34298551 DOI: 10.1093/ehjcvp/pvab049] [Reference Citation Analysis]
24 Harikrishnan S, Mohanan PP, Chopra VK, Ambuj R, Sanjay G, Bansal M, Chakraborty RN, Chandra S, Chattarjee SS, Chopra HK, Mathew C, Deb PK, Goyal A, Goswami KC, Gupta R, Guha S, Gupta V, Hasija PK, Wardhan H, Jabir A, Jayagopal PB, Kahali D, Katyal VK, Kerkar PG, Khanna NN, Majumder B, Mandal M, Meena CB, Naik N, Narain VK, Pathak LA, Ray S, Roy D, Routray SN, Sarma D, Shanmugasundaram S, Singh BP, Tyagi SK, Venugopal K, Wander GS, Yadav R, Das MK. Cardiological society of India position statement on COVID-19 and heart failure. Indian Heart J 2020;72:75-81. [PMID: 32405088 DOI: 10.1016/j.ihj.2020.04.012] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
25 Sankhe R, Rathi E, Manandhar S, Kumar A, Pai SRK, Kini SG, Kishore A. Repurposing of existing FDA approved drugs for Neprilysin inhibition: An in-silico study. J Mol Struct 2021;1224:129073. [PMID: 32834116 DOI: 10.1016/j.molstruc.2020.129073] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
26 Roganović JR. microRNA-146a and -155, upregulated by periodontitis and type 2 diabetes in oral fluids, are predicted to regulate SARS-CoV-2 oral receptor genes. J Periodontol 2021;92:35-43. [PMID: 33336412 DOI: 10.1002/JPER.20-0623] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
27 Wong SY, Brubaker AL, Wang AX, Taiwo AA, Melcher ML. What solid organ transplant healthcare providers should know about renin-angiotensin-aldosterone system inhibitors and COVID-19. Clin Transplant 2020;34:e13991. [PMID: 32446267 DOI: 10.1111/ctr.13991] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
28 DeFilippis EM, Reza N, Donald E, Givertz MM, Lindenfeld J, Jessup M. Considerations for Heart Failure Care During the COVID-19 Pandemic. JACC Heart Fail 2020;8:681-91. [PMID: 32493638 DOI: 10.1016/j.jchf.2020.05.006] [Cited by in Crossref: 28] [Cited by in F6Publishing: 33] [Article Influence: 14.0] [Reference Citation Analysis]
29 Acanfora D, Acanfora C, Ciccone MM, Scicchitano P, Bortone AS, Uguccioni M, Casucci G. The Cross-Talk between Thrombosis and Inflammatory Storm in Acute and Long-COVID-19: Therapeutic Targets and Clinical Cases. Viruses 2021;13:1904. [PMID: 34696334 DOI: 10.3390/v13101904] [Reference Citation Analysis]
30 Kunnumakkara AB, Rana V, Parama D, Banik K, Girisa S, Henamayee S, Thakur KK, Dutta U, Garodia P, Gupta SC, Aggarwal BB. COVID-19, cytokines, inflammation, and spices: How are they related? Life Sci 2021;:119201. [PMID: 33607159 DOI: 10.1016/j.lfs.2021.119201] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]